GO:0010667 negative regulation of cardiac muscle cell apoptotic process: Signaling Pathways, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0010667 describes any biological process that decreases the rate or extent of apoptosis specifically in cardiac muscle cells, a key protective mechanism in the heart.
• Dysregulation of this process contributes to ischemia/reperfusion injury, diabetic cardiomyopathy, heart failure, and pathological hypertrophy.
• Key molecular players include Hmbox1, Gck, PPARβ/δ, BDH1, PDE4B, FGF18, Prmt7, and myostatin, which modulate survival signaling, metabolism, and inflammation.
• Experimental models such as knockout, point-mutation, knock-in, and overexpression in mice and cell lines are essential to dissect causal roles of candidate genes.
• CRISPR-based screens and bioinformatics can identify novel regulators of cardiomyocyte apoptosis, accelerating therapeutic target discovery.
• Understanding this process offers opportunities for cardioprotective therapies in ischemic heart disease, diabetes, and heart failure.
Description
Cardiac muscle cell apoptosis is a form of programmed cell death that contributes to myocardial injury and heart failure progression. The Gene Ontology term GO:0010667, negative regulation of cardiac muscle cell apoptotic process, encompasses all molecular events that suppress this death program, thereby preserving cardiomyocyte viability and cardiac function. Research into this process has revealed critical signaling nodes, metabolic regulators, and epigenetic modifiers that protect the heart under stress. Understanding these mechanisms is essential for developing therapies that limit cardiomyocyte loss in ischemic and diabetic heart disease.
negative regulation of cardiac muscle cell apoptotic process At A Glance
| GO ID | GO:0010667 |
|---|---|
| GO term | negative regulation of cardiac muscle cell apoptotic process |
| Ontology | biological_process |
| Synonym | down regulation of cardiac muscle cell apoptosis; down-regulation of cardiac muscle cell apoptosis; downregulation of cardiac muscle cell apoptosis; inhibition of cardiac muscle cell apoptosis; negative regulation of cardiac muscle cell apoptosis |
| Major function | Suppression of programmed cell death in cardiomyocytes, preserving cardiac contractile function and tissue integrity |
| Related processes | Apoptotic signaling, oxidative stress response, metabolic regulation, inflammation, and fibrosis |
| Key regulators | Hmbox1, Gck, PPARβ/δ, BDH1, PDE4B, FGF18, Prmt7, myostatin |
| Disease relevance | Ischemia/reperfusion injury, diabetic cardiomyopathy, heart failure, pathological hypertrophy |
What Is GO:0010667?
GO:0010667 is defined as any process that decreases the rate or extent of cardiac cell apoptotic process, a form of programmed cell death induced by external or internal signals that trigger the activity of proteolytic caspases whose actions dismantle a cardiac muscle cell and result in its death. In simpler terms, it is the set of biological mechanisms that keep heart muscle cells alive by blocking apoptosis.
Why Is negative regulation of cardiac muscle cell apoptotic process Important in Cell Biology?
Cardiomyocyte apoptosis is a major contributor to myocardial damage in ischemic heart disease, diabetic cardiomyopathy, and heart failure. Elucidating the negative regulation of this process provides mechanistic insights into cardioprotection and identifies therapeutic targets to limit cell death and preserve cardiac function.
• Prevents cardiomyocyte loss during ischemia/reperfusion injury.
• Mitigates diabetic cardiomyopathy by reducing apoptosis and fibrosis.
• Preserves cardiac function in heart failure by blunting maladaptive remodeling.
• Attenuates pathological cardiac hypertrophy under stress.
• Regulates metabolic and inflammatory pathways that influence cell survival.
• Involves epigenetic and post-translational mechanisms that can be targeted.
• Provides biomarkers and therapeutic targets for cardiovascular disease.
• Enables high-throughput screening for cardioprotective compounds.
• Informs precision medicine approaches for patients with genetic predispositions.
• Guides development of gene therapies to enhance cardiomyocyte resilience.
What Happens During negative regulation of cardiac muscle cell apoptotic process?
Initiation of survival signaling
In simple terms: The heart cell receives signals that tell it to stay alive.
Negative regulation begins with the activation of pro-survival pathways that counteract apoptotic stimuli. For example, inhibition of Hmbox1 promotes cardiomyocyte survival through activation of glucokinase (Gck), enhancing glucose metabolism and reducing apoptosis during ischemia/reperfusion injury. Similarly, PPARβ/δ activation prevents inflammation and fibrosis, indirectly supporting cardiomyocyte survival in diabetic cardiomyopathy.
Suppression of apoptotic effectors
In simple terms: The cell blocks the proteins that would otherwise dismantle it.
This step involves inhibiting caspases and other pro-apoptotic factors. BDH1 overexpression alleviates diabetic cardiomyopathy by inhibiting H3K9bhb-mediated transcriptional activation of LCN2, which reduces apoptosis. PDE4B overexpression blunts β-adrenergic response and maladaptive remodeling, partly by modulating cAMP signaling that influences apoptosis.
Metabolic and epigenetic reprogramming
In simple terms: The cell changes its metabolism and gene expression to resist death.
Metabolic shifts and epigenetic modifications contribute to apoptosis resistance. Hmbox1 inhibition enhances glucose metabolism via Gck, supporting survival. BDH1 affects histone β-hydroxybutyrylation, altering gene expression to protect cardiomyocytes. Prmt7 regulates JAK/STAT/Socs3 signaling, impacting postmenopausal cardiomyopathy and cell survival.
Modulation of inflammation and fibrosis
In simple terms: Reducing inflammation and scarring helps heart cells survive.
Negative regulation of apoptosis is often coupled with reduced inflammation and fibrosis. PPARβ/δ prevents inflammation and fibrosis during diabetic cardiomyopathy, creating a pro-survival environment. FGF18 alleviates stress-induced pathological cardiac hypertrophy, likely by suppressing pro-apoptotic and pro-fibrotic signals.
Integration of systemic signals
In simple terms: Hormones and growth factors from the body influence heart cell survival.
Systemic factors such as myostatin alterations are associated with changes in cardiac left ventricular mass, though not ejection fraction, indicating a role in cardiac remodeling that may intersect with apoptosis regulation. Suxiao Jiuxin Pill alleviates myocardial ischemia/reperfusion-induced autophagy via miR-193a-3p/ALKBH5 pathway, highlighting cross-talk between autophagy and apoptosis regulation.
Key Genes Involved in GO:0010667 negative regulation of cardiac muscle cell apoptotic process
The following genes and proteins have been experimentally implicated in the negative regulation of cardiac muscle cell apoptotic process.
| Gene | Major Role | Research Relevance |
|---|---|---|
| Hmbox1 | Inhibition promotes cardiomyocyte survival via Gck activation | Target for ischemia/reperfusion injury therapy |
| Gck | Mediates glucose metabolism and survival downstream of Hmbox1 | Metabolic regulator of cardiomyocyte apoptosis |
| PPARβ/δ | Prevents inflammation and fibrosis, supporting survival | Therapeutic target in diabetic cardiomyopathy |
| BDH1 | Overexpression inhibits H3K9bhb-mediated LCN2 activation | Epigenetic regulator of apoptosis in diabetes |
| LCN2 | Pro-apoptotic factor suppressed by BDH1 | Biomarker and target in diabetic cardiomyopathy |
| PDE4B | Blunts β-adrenergic response and maladaptive remodeling | Modulator of cAMP signaling in heart failure |
| FGF18 | Alleviates stress-induced pathological cardiac hypertrophy | Growth factor with cardioprotective potential |
| Prmt7 | Regulates JAK/STAT/Socs3 signaling | Epigenetic enzyme in postmenopausal cardiomyopathy |
| Socs3 | Downstream effector of Prmt7 in JAK/STAT pathway | Inflammation modulator in cardiomyopathy |
| Myostatin | Alters left ventricular mass but not ejection fraction | Systemic regulator of cardiac remodeling |
| miR-193a-3p | Regulates ALKBH5 in autophagy/apoptosis cross-talk | Non-coding RNA target in ischemia/reperfusion |
| ALKBH5 | RNA demethylase involved in autophagy regulation | Epitranscriptomic regulator of cell survival |
| JAK | Kinase in Prmt7-regulated pathway | Signaling node in cardiomyopathy |
| STAT | Transcription factor downstream of JAK | Mediator of gene expression in cardiomyopathy |
| Caspases | Proteolytic enzymes executing apoptosis | Direct targets for inhibition |
| β-adrenergic receptors | Mediate stress response modulated by PDE4B | Receptor targets in heart failure |
| Glucokinase | Enzyme in glucose metabolism | Metabolic checkpoint for survival |
| Histone H3K9bhb | Epigenetic mark modulated by BDH1 | Chromatin modification in apoptosis |
How Is negative regulation of cardiac muscle cell apoptotic process Regulated?
The negative regulation of cardiac muscle cell apoptotic process is controlled by a network of signaling pathways, including the Hmbox1-Gck metabolic axis, PPARβ/δ anti-inflammatory signaling, BDH1-dependent epigenetic regulation, PDE4B-mediated cAMP modulation, FGF18 signaling, and Prmt7-JAK/STAT/Socs3 pathway. These pathways integrate metabolic, inflammatory, and stress signals to determine cardiomyocyte fate.
negative regulation of cardiac muscle cell apoptotic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| Hmbox1 | Ischemia/reperfusion injury | Cardiomyocyte-specific knockout and overexpression mice |
| PPARβ/δ | Diabetic cardiomyopathy | Agonist treatment in diabetic mouse models |
| BDH1 | Diabetic cardiomyopathy | Overexpression in cardiomyocytes and diabetic mice |
| PDE4B | Heart failure | Cardiac-specific overexpression in mice |
| FGF18 | Pathological cardiac hypertrophy | FGF18 knockout and overexpression mice |
Ischemia/Reperfusion Injury
During myocardial ischemia/reperfusion, cardiomyocyte apoptosis contributes to tissue damage. Inhibition of Hmbox1 promotes cardiomyocyte survival and glucose metabolism through Gck activation, reducing apoptosis and improving outcomes in ischemia/reperfusion injury. Suxiao Jiuxin Pill alleviates autophagy via miR-193a-3p/ALKBH5, highlighting additional regulatory layers.
Diabetic Cardiomyopathy
In diabetic cardiomyopathy, hyperglycemia and inflammation increase cardiomyocyte apoptosis. PPARβ/δ activation prevents inflammation and fibrosis, protecting the heart. BDH1 overexpression alleviates diabetic cardiomyopathy by inhibiting H3K9bhb-mediated transcriptional activation of LCN2, reducing apoptosis.
Heart Failure and Pathological Hypertrophy
Heart failure involves progressive cardiomyocyte loss and maladaptive remodeling. PDE4B overexpression blunts β-adrenergic response and maladaptive remodeling in heart failure. FGF18 alleviates stress-induced pathological cardiac hypertrophy, likely by suppressing pro-apoptotic signaling.
Postmenopausal Cardiomyopathy
Prmt7 regulates the JAK/STAT/Socs3 signaling pathway in postmenopausal cardiomyopathy, influencing cardiomyocyte survival and inflammation. Myostatin alterations are associated with changes in left ventricular mass, indicating a role in cardiac remodeling.
From negative regulation of cardiac muscle cell apoptotic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene increase apoptosis? | Knockout mice or CRISPR-Cas9 knockout in cardiomyocytes |
| Does a specific mutation alter survival signaling? | Point-mutation knock-in mice or cell lines |
| Does overexpression protect against apoptosis? | Transgenic overexpression in mice or lentiviral overexpression in vitro |
| Where is the protein localized during stress? | Tagged knock-in with fluorescent reporter |
| What genes are essential for survival? | CRISPR library screening in cardiomyocytes |
| How does a drug affect apoptosis? | Pharmacological intervention in ischemia/reperfusion models |
How to Study the negative regulation of cardiac muscle cell apoptotic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Gene expression changes | Identify survival pathways |
| ChIP-seq | Histone modifications and TF binding | Epigenetic regulation of apoptosis |
| Proteomics | Protein abundance and modifications | Signaling pathway analysis |
| TUNEL assay | Apoptotic cell death | Quantify cardiomyocyte apoptosis |
| Caspase activity assay | Caspase enzymatic activity | Measure apoptosis execution |
| CRISPR screen | Gene essentiality for survival | Discover novel regulators |
| Bioinformatics | Pathway enrichment and network analysis | Integrate multi-omics data |
Transcriptomic and Epigenomic Profiling
RNA-seq and ChIP-seq can identify gene expression changes and epigenetic marks such as H3K9bhb that regulate apoptosis. These methods reveal pathways modulated by BDH1 and other regulators.
Proteomic and Phosphoproteomic Analysis
Mass spectrometry-based proteomics can quantify apoptotic and survival proteins, uncovering signaling nodes like JAK/STAT/Socs3 regulated by Prmt7.
Functional Assays for Apoptosis
TUNEL staining, caspase activity assays, and flow cytometry measure apoptosis rates in cardiomyocytes under stress, as used in studies of Hmbox1 and PPARβ/δ.
CRISPR Screening and Bioinformatics
Genome-wide CRISPR knockout screens combined with bioinformatics can identify novel negative regulators of cardiomyocyte apoptosis, as demonstrated in ischemia/reperfusion studies.
How CRISPR Can Be Used to Study GO:0010667 negative regulation of cardiac muscle cell apoptotic process
Knockout
CRISPR-Cas9 knockout of candidate genes such as Hmbox1 or BDH1 in cardiomyocytes or mouse models can determine whether loss of function increases or decreases apoptosis under stress.
Point Mutation
Introducing specific point mutations (e.g., in Gck or PPARβ/δ) via CRISPR can dissect the contribution of individual amino acids to survival signaling and metabolic regulation.
Knock-in
Knock-in of tagged versions of proteins like PDE4B or FGF18 allows real-time tracking of localization and interactions during apoptosis regulation.
Overexpression
CRISPR activation (CRISPRa) or transgenic overexpression of protective genes such as BDH1 or FGF18 can test sufficiency for cardioprotection in disease models.
How EDITGENE Supports negative regulation of cardiac muscle cell apoptotic process Research
Researchers studying negative regulation of cardiac muscle cell apoptotic process-related genes often need to determine whether a candidate gene is causally involved in cardiomyocyte survival or death. EDITGENE provides comprehensive CRISPR-based services to accelerate this discovery.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of cardiac muscle cell apoptotic process research.
Frequently Asked Questions About negative regulation of cardiac muscle cell apoptotic process
What is GO:0010667?
GO:0010667 is the Gene Ontology term for negative regulation of cardiac muscle cell apoptotic process, describing any biological process that decreases the rate or extent of apoptosis in cardiac muscle cells.
What genes are involved in negative regulation of cardiac muscle cell apoptotic process?
Key genes include Hmbox1, Gck, PPARβ/δ, BDH1, PDE4B, FGF18, Prmt7, and myostatin, among others.
How does Hmbox1 regulate cardiomyocyte survival?
Inhibition of Hmbox1 promotes cardiomyocyte survival and glucose metabolism through Gck activation in ischemia/reperfusion injury.
What is the role of BDH1 in diabetic cardiomyopathy?
BDH1 overexpression alleviates diabetic cardiomyopathy by inhibiting H3K9bhb-mediated transcriptional activation of LCN2, reducing apoptosis.
How does PPARβ/δ prevent cardiac apoptosis?
PPARβ/δ prevents inflammation and fibrosis during diabetic cardiomyopathy, creating a pro-survival environment.
What experimental models are used to study this process?
Knockout, point-mutation, knock-in, and overexpression mouse models, as well as CRISPR screens in cardiomyocytes, are commonly used.
What diseases are linked to dysregulation of this process?
Ischemia/reperfusion injury, diabetic cardiomyopathy, heart failure, and pathological cardiac hypertrophy.
How can CRISPR screening identify new regulators?
Genome-wide CRISPR knockout screens in cardiomyocytes under stress can reveal genes whose loss increases or decreases apoptosis.
What methods measure cardiomyocyte apoptosis?
TUNEL staining, caspase activity assays, and flow cytometry are standard methods.
Why is negative regulation of cardiac muscle cell apoptosis important for therapy?
Enhancing this process can protect the heart from ischemic and diabetic injury, preserving cardiac function.
Conclusion
GO:0010667 encompasses critical protective mechanisms that keep cardiomyocytes alive under stress. Research has identified diverse regulators, from metabolic enzymes like Gck to epigenetic modifiers like BDH1, offering multiple therapeutic targets. Continued investigation using CRISPR models and multi-omics approaches will further unravel this process and translate findings into cardioprotective therapies.
References
- 1. Bei Y et al.. 2024. Inhibition of Hmbox1 Promotes Cardiomyocyte Survival and Glucose Metabolism Through Gck Activation in Ischemia/Reperfusion Injury.. Circulation 150(11):848-866 PMID: 38708602
- 2. Wang D et al.. 2024. Suxiao Jiuxin Pill alleviates myocardial ischemia/reperfusion-induced autophagy via miR-193a-3p/ALKBH5 pathway.. Phytomedicine 125:155359 PMID: 38301300
- 3. Rostami A et al.. 2024. PPARβ/δ prevents inflammation and fibrosis during diabetic cardiomyopathy.. Pharmacol Res 210:107515 PMID: 39577755
- 4. Xu BT et al.. 2025. BDH1 overexpression alleviates diabetic cardiomyopathy through inhibiting H3K9bhb-mediated transcriptional activation of LCN2.. Cardiovasc Diabetol 24(1):101 PMID: 40022118
- 5. Karam S et al.. 2020. Cardiac Overexpression of PDE4B Blunts β-Adrenergic Response and Maladaptive Remodeling in Heart Failure.. Circulation 142(2):161-174 PMID: 32264695
- 6. Chen G et al.. 2023. Fibroblast growth factor 18 alleviates stress-induced pathological cardiac hypertrophy in male mice.. Nat Commun 14(1):1235 PMID: 36871047
- 7. Ahn BY et al.. 2024. Prmt7 regulates the JAK/STAT/Socs3 signaling pathway in postmenopausal cardiomyopathy.. Exp Mol Med 56(3):711-720 PMID: 38486105
- 8. Artaza JN et al.. 2007. Alterations in myostatin expression are associated with changes in cardiac left ventricular mass but not ejection fraction in the mouse.. J Endocrinol 194(1):63-76 PMID: 17592022
